EGFR and non-small cell lung carcinoma: Osimertinib (AZD9291 or TAGRISSOTM) is representative of the third generation of EGFR-TKIs and has been approved by the FDA for patients with locally advanced NSCLC or NSCLC patients who are positive for the EGFR T790 M mutation.